Opioid Treatment Adoption Uneven Across U.S
A Rutgers Health study reveals a tenfold increase in the use of long-acting injectable buprenorphine for opioid use disorder between 2021 and 2024. While adoption is growing, researchers noted significant regional disparities in how the medication is being utilized across the U.S.
Why it matters
Improving access to long-acting addiction treatments is critical for reducing overdose risks and stabilizing patients who struggle with daily oral medication regimens.
There was a substantial increase in recent years in the use of a form of the primary medication to treat opioid use disorder, according to a Rutgers Health study.
The report relies on academic research data and provides a balanced overview of medical trends without political framing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in